FGF-21

FGF-21

FGF-21 Overview

Molecule Name
Fibroblast growth factor 21
Synonyms
FGF-21, FGF21
Drug Development Progress
Drugs in Clinical Trials10
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
FGF21
Background
Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.

FGF-21 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
PegozaferminBIO89-100; TEV-47948Phase 3 ClinicalTeva Pharmaceutical Industries Ltd
Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
Efimosfermin alfaLLF-580; BOS-580; GSK-6519754Phase 3 ClinicalNovartis Pharma Ag
Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
Details
EfruxiferminAKR-001; AMG-876; EFX; Fc-FGF21(RGE)Phase 3 ClinicalAmgen Inc
Diabetes Mellitus; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
MWN-105MWN-105Phase 2 ClinicalShanghai Minwei Biotechnology Co Ltd
Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight
Details
TQA-2225AP-025; TQA2225; TQA-2225Phase 2 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
HEC-88473HEC-88473; HEC88473; APL-18881Phase 2 ClinicalDongguan Hec Taigen Biopharmaceuticals Co Ltd
Diabetes Mellitus, Type 2; Hepatitis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
Details
B-1344B-1344Phase 1 ClinicalTasly Biomedical Co Ltd
Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
DMR-2301DMR-2301; DMR2301Phase 1 ClinicalShanghai Duomirui Biotechnology Co Ltd
Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
ZT-003ZT003; ZT-003Phase 1 ClinicalBeijing QL Biopharmaceutical Co Ltd
Diabetes Mellitus; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
Details
AP-026TQA2226; AP026; AP-026; TQA-2226Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight
Details